
Avinash Chaurasia
@chaurasiamd
Army Rad Onc in San Antonio. #DEIinRO / #Leadership / #Mentorship / #MedEd He/Him/His
ID: 1122875345781297157
29-04-2019 14:48:39
2,2K Tweet
2,2K Followers
2,2K Following


#RADIOSA Trial: SBRT vs SBRT+ADT for oligorecurrent #ProstateCancer. Giulia Marvaso shares findings from the RADIOSA trial, comparing SBRT alone vs. SBRT + short-course hormonal therapy in oligorecurrent #PCa. Results show enhanced biochemical and clinical progression-free


We are very excited to share the same IJROBP - The Red Journal issue with this novel study of SAbR for early-stage larynx cancer from IRE ISG IFO redjournal.org/article/S0360-…







Join us tomorrow, 3/5, for our next Med Student Q&A on at 8 pm ET. These sessions feature a RadOnc & a RadOnc resident & provide a platform for med students to learn more about the specialty. ➡️Sign-up here: ow.ly/GwfU50TM8lx ARRO LMSA National The Student National Medical Association (SNMA) Radiation Oncology Program Directors


Congrats to Giulia Marvaso prof. Barbara Jereczek-Fossa Piet Ost Chad Tang, MD on the RADIOSA trial, which randomized patients with omHSPC to SBRT vs. SBRT+6 months ADT thelancet.com/journals/lanon…

Avinash Chaurasia Sean Collins Prostate SBRT @ USF Health Well put Sean Collins Prostate SBRT @ USF Health! I think conventional size restriction can be relaxed as we get more comfortable with SBRT. Speaking to this, NRG Oncology’s recent GU013 allows patients with ≤100 cc whereas GU005 was capped at 70cc. Papers which might be of interest PMIDs: 37984713, 36836467




Most viewed in the last 7 days from JAMA Oncology: For select breast cancer patients with complete response to neoadjuvant systemic therapy, radiotherapy alone without breast surgery may be feasible, as no tumor recurrences were observed at 5-year follow-up. ja.ma/42jxjDs




What makes strong multidisciplinary cancer care work? In this RadOnc Report podcast episode, Avinash Chaurasia, MD, talks with Eric Singhi, MD, and Timothy Vreeland, MD, about building better collaboration across specialties. 🎧 Listen here: ow.ly/fyzK50VS05N Avinash Chaurasia

